In context
Glepaglutide was evaluated in a placebo-controlled phase 3 trial in adults with short bowel syndrome and intestinal failure requiring parenteral support. [1]
At a glance
- Type
- Peptide / related clinical research
- Regulatory context
- The cited source describes research, not a determination of present marketing authorisation. Country, formulation and indication must be checked separately.
- Evidence
- The study compared support requirements over 24 weeks. Its specialised disease setting and measured outcomes do not generalise to routine digestive complaints.
How to interpret this evidence
The study compared support requirements over 24 weeks. Its specialised disease setting and measured outcomes do not generalise to routine digestive complaints. [1]
Safety and clinical context
The evidence described here does not establish safety for unsupervised use. Product identity, route, formulation, interactions and long-term effects cannot be inferred from a study category.
Evidence and authorisation depend on the product, formulation, indication and country. US labelling does not establish Thai authorisation. This guide is educational and is not a dosing or self-treatment protocol.
Primary sources
Read the underlying source and its limitations. A study citation does not by itself establish efficacy or approval.